(Q44658058)

5 December 2017

The effect of everolimus versus mycophenolate upon proteinuria following kidney transplant and relationship to graft outcomes (English)

1 reference

5 December 2017

A C Wiseman

1

1 reference

5 December 2017

K McCague

2

1 reference

5 December 2017

Y Kim

3

1 reference

5 December 2017

F Geissler

4

1 reference

5 December 2017

M Cooper

5

1 reference

5 December 2017

language of work or name

English

0 references

publication date

3 December 2012

1 reference

American Journal of Transplantation

5 December 2017

1 reference

5 December 2017

13

1 reference

5 December 2017

2

1 reference

5 December 2017

442-449

1 reference

Proteinuria after kidney transplantation, relationship to allograft histology and survival

5 December 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2012.04334.X

Proteinuria after renal transplantation affects not only graft survival but also patient survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2012.04334.X

Significance and management of proteinuria in kidney transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2012.04334.X

Management of side effects of sirolimus therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2012.04334.X

Development of proteinuria after switch to sirolimus-based immunosuppression in long-term cardiac transplant patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2012.04334.X

Sirolimus interacts with pathways essential for podocyte integrity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2012.04334.X

Loss of nephrin expression in glomeruli of kidney-transplanted patients under m-TOR inhibitor therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2012.04334.X

Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2012.04334.X

Predictors of success in conversion from calcineurin inhibitor to sirolimus in chronic allograft dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2012.04334.X

Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2012.04334.X

Everolimus plus reduced-exposure CsA versus mycophenolic acid plus standard-exposure CsA in renal-transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2012.04334.X

Rapid resolution of proteinuria of native kidney origin following live donor renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2012.04334.X

Proteinuria in kidney transplant recipients: prevalence, prognosis, and evidence-based management

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2012.04334.X

Very low-grade proteinuria at 3 months posttransplantation is an earlier marker of graft survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2012.04334.X

Risk factors and prognosis for proteinuria in renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2012.04334.X

10.1111/J.1600-6143.2012.04334.X

21 January 2018

Identifiers

DOI

1 reference

5 December 2017

1 reference